Cover Image
市場調查報告書

EpiCast Report:抗藥性金黃色葡萄球菌 (MRSA) 的流行病學預測 2024年

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 345360
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:抗藥性金黃色葡萄球菌 (MRSA) 的流行病學預測 2024年 EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024
出版日期: 2015年10月13日 內容資訊: 英文 62 Pages
簡介

在2014年中,主要7個市場 (美國、法國、德國、義大利、西班牙、英國及日本) 的抗藥性金黃色葡萄球菌 (MRSA) 的感染住院案例達了79萬7,883件。這個數字預計至2024年增加到88萬4,727件。住院案例在美國、法國、義大利、西班牙、英國及日本增加,不過,在德國減少。

本報告提供全球主要7個市場的抗藥性金黃色葡萄球菌 (MRSA) 的診斷病例數及住院患者數的變遷相關調查、今後10年的預測、疾病的背景、風險要素和並存症、各年齡/性別/感染地方的診斷病例數、預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法
  • 抗藥性金黃色葡萄球菌 (MRSA) 流行病學的預測
    • MRSA的住院案例
    • MRSA的住院案例:性別
    • MRSA的住院案例:各年齡
    • MRSA的住院案例:年齡調整比率
    • MRSA的住院案例的比例:各感染場所
    • MRSA的住院案例的比例:病例定義
  • 檢驗
    • 流行病學的預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER097-15

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

  • The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
  • The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MRSA market.
  • Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
  • Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for MRSA (2014-2024)
    • 3.5.1. Hospitalized Incident Cases of MRSA
    • 3.5.2. Sex-Specific Hospitalized Incident Cases of MRSA
    • 3.5.3. Age-Specific Hospitalized Incidence of MRSA
    • 3.5.4. Age-Standardized Hospitalized Incidence Rate of MRSA
    • 3.5.5. Proportion of Hospitalized Incident MRSA Cases by Infection Site
    • 3.5.6. Proportion of Hospitalized Incident MRSA Cases by Case Definition
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for MRSA
  • Table 2: Definitions of HA-MRSA and CA-MRSA
  • Table 3: US, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 4: France, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 5: Germany, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 6: Italy, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 7: Spain, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 8: UK, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 9: Japan, Sources Used to Calculate the MRSA Incident Cases Arising from Pneumonias, SSTIs, and BSIs
  • Table 10: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024
  • Table 11: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014
  • Table 12: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014

List of Figures

  • Figure 1: US, Methodology for Calculation of MRSA Hospitalized Incident Cases
  • Figure 2: 5EU, Methodology Used to Calculate the MRSA Hospitalized Incident Cases by Infection Type
  • Figure 3: 7MM, Hospitalized Incident Cases of MRSA, Men and Women, All Ages, N, 2014-2024
  • Figure 4: 7MM, Sex-Specific Hospitalized Incident Cases of MRSA, All Ages, N, 2014
  • Figure 5: 7MM, Age-Specific Hospitalized Incident Cases of MRSA, Men and Women, N, 2014
  • Figure 6: 7MM, Age-Standardized Hospitalized Incidence Rate of MRSA, 2014
  • Figure 7: 7MM, Proportion of Hospitalized Incident MRSA Cases by Infection Site, Men and Women, All Ages
  • Figure 8: 7MM, Proportion of Hospitalized Incident MRSA Cases by Case Definition, Men and Women, All Ages
Back to Top